• Healthy men or non-pregnant, non-lactating healthy women of non-childbearing potential, 18-60 years of age.

• Must agree to use a highly effective method of contraception.

• Body Mass Index (BMI) 18-33 kg/m2 as measured at screening.

• Weight ≤100 kg at screening.

• Normal lung function, defined as: FVC and FEV1 \> 80% predicted (based on age, height, race, sex, SaO2 \> 95% on room air.

• Heart rate between 50 and 90 beats per minute (BPM).

• Good state of health (mentally and physically) as indicated by a comprehensive clinical assessment (detailed medical history and a complete physical examination) and screening safety procedures.

• Diagnosis of IPF by American Thoracic Society/ERS (European Respiratory Society)/JRS (Japanese Respiratory Society)/ALAT (Latin America Thoracic Society) 2011 criteria within five years prior to consent.

• Men or non-pregnant, non-lactating women of non-childbearing potential.

• Age ≥ 40 years.

• Mild to moderate IPF as defined by predicted FVC ≥ 55% of normal and predicted DLCO \> 40% of normal at Screening.

• Subjects receiving oral pirfenidone or nintedanib for treatment of IPF may participate if they have been on treatment with a stable, well-tolerated dose (as determined by the investigator), for at least 8 weeks prior to consent with no changes to therapy dose and schedule anticipated during the course of study participation.

• Must be able to understand a written informed consent, which must be obtained prior to any study procedures.

• Must be willing and able to comply with all study requirements